PKI-402PI3K inhibitor,selective, reversible and ATP-competitive CAS# 1173204-81-3 |
- IPI-145 (INK1197)
Catalog No.:BCC1104
CAS No.:1201438-56-3
- IC-87114
Catalog No.:BCC1161
CAS No.:371242-69-2
- PI-103
Catalog No.:BCC1162
CAS No.:371935-74-9
- PIK-75
Catalog No.:BCC1163
CAS No.:372196-77-5
- TGX-221
Catalog No.:BCC1244
CAS No.:663619-89-4
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1173204-81-3 | SDF | Download SDF |
PubChem ID | 44187953 | Appearance | Powder |
Formula | C29H34N10O3 | M.Wt | 570.65 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 5 mg/mL (8.76 mM; Need ultrasonic) | ||
Chemical Name | 1-[4-(3-ethyl-7-morpholin-4-yltriazolo[4,5-d]pyrimidin-5-yl)phenyl]-3-[4-(4-methylpiperazine-1-carbonyl)phenyl]urea | ||
SMILES | CCN1C2=C(C(=NC(=N2)C3=CC=C(C=C3)NC(=O)NC4=CC=C(C=C4)C(=O)N5CCN(CC5)C)N6CCOCC6)N=N1 | ||
Standard InChIKey | ZAXFYGBKZSQBIV-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C29H34N10O3/c1-3-39-27-24(34-35-39)26(37-16-18-42-19-17-37)32-25(33-27)20-4-8-22(9-5-20)30-29(41)31-23-10-6-21(7-11-23)28(40)38-14-12-36(2)13-15-38/h4-11H,3,12-19H2,1-2H3,(H2,30,31,41) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | PKI-402 is a potent dual inhibitor of PI3K/mTOR with IC50 values of 2 nM/7 nM/16 nM/14 nM and 3 nM for PI3Kα/β/γ/δ and mTOR, respectively. | ||||||
Targets | PI3Kα | mTOR | PI3Kβ | PI3Kδ | PI3Kγ | ||
IC50 | 2 nM | 3 nM | 7 nM | 14 nM | 16 nM |
PKI-402 Dilution Calculator
PKI-402 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
PKI-402 is a selective, equipotent and ATP-competitive class I PI3K inhibitor (IC50= 1 nM, 7 nM, 16 nM and 14 nM for PI3Kα, PI3Kβ, PI3Kγ and PI3Kδ, respectively.)
PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) is a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. It plays a key role in PI3K/Akt/mTOR pathway.
In multiple human cancer cell lines (e.g. breast, brain, pancreas and NSCL), PKI-402 inhibited growth of cancer cells, and attenuated phosphorylation of effector of PI3K and mTOR. In MDA-MB-361, 30 nM PKI-402 caused cleaved of the apoptosis marker—PARP.
In MDA-MB-361 mouse tumor xenograft models, administration of 100 mg/kg of PKI-402 daily for 5 days decreased the initial tumor volume from 260 mm3 to 129 mm3 and inhibited tumor regrowth for 70 days, single dose of PKI-402 blocked phosphorylation of Akt and led to cleaved PARP.
Reference:
1. Mallon R, Hollander I, Feldberg L et al. Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor. Mol Cancer Ther. 2010 Apr;9(4):976-84.
- U0126-EtOH
Catalog No.:BCC1066
CAS No.:1173097-76-1
- GW 583340 dihydrochloride
Catalog No.:BCC7300
CAS No.:1173023-85-2
- STO-609 acetate
Catalog No.:BCC7112
CAS No.:1173022-21-3
- RS 102895 hydrochloride
Catalog No.:BCC7260
CAS No.:1173022-16-6
- gamma-secretase modulator 1
Catalog No.:BCC1583
CAS No.:1172637-87-4
- 8alpha-Hydroxylabda-13(16),14-dien-19-yl p-hydroxycinnamate
Catalog No.:BCN1609
CAS No.:117254-98-5
- Soyasaponin Aa
Catalog No.:BCN2597
CAS No.:117230-33-8
- Taxacin
Catalog No.:BCN6950
CAS No.:117229-54-6
- HO-3867
Catalog No.:BCC5639
CAS No.:1172133-28-6
- PI3Kγ inhibitor 1
Catalog No.:BCC4180
CAS No.:1172118-03-4
- M 1145
Catalog No.:BCC6053
CAS No.:1172089-00-7
- Sophoraisoflavone A
Catalog No.:BCN6826
CAS No.:117204-81-6
- Clocinnamox mesylate
Catalog No.:BCC5684
CAS No.:117332-69-1
- Emeheterone
Catalog No.:BCN7285
CAS No.:117333-12-7
- 9,9-Bis[4-(2-hydroxyethoxy)phenyl]fluorene
Catalog No.:BCC8796
CAS No.:117344-32-8
- 2-Hydroxysaclofen
Catalog No.:BCC6579
CAS No.:117354-64-0
- AZD6482
Catalog No.:BCC2523
CAS No.:1173900-33-8
- Endothelin 3 (human, rat)
Catalog No.:BCC5713
CAS No.:117399-93-6
- Artoheterophyllin B
Catalog No.:BCN6050
CAS No.:1174017-37-8
- Dimethylwulignan A1
Catalog No.:BCN3624
CAS No.:117404-43-0
- AZD2461
Catalog No.:BCC2214
CAS No.:1174043-16-3
- 4-O-beta-Glucopyranosyl-cis-coumaric acid
Catalog No.:BCN1608
CAS No.:117405-48-8
- D-CPP-ene
Catalog No.:BCC6999
CAS No.:117414-74-1
- 2-Methyl-6-(p-tolyl)heptane-2,3-diol
Catalog No.:BCN7249
CAS No.:117421-22-4
Antitumor efficacy profile of PKI-402, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor.[Pubmed:20371716]
Mol Cancer Ther. 2010 Apr;9(4):976-84.
PKI-402 is a selective, reversible, ATP-competitive, equipotent inhibitor of class I phosphatidylinositol 3-kinases (PI3K), including PI3K-alpha mutants, and mammalian target of rapamycin (mTOR; IC(50) versus PI3K-alpha = 2 nmol/L). PKI-402 inhibited growth of human tumor cell lines derived from breast, brain (glioma), pancreas, and non-small cell lung cancer tissue and suppressed phosphorylation of PI3K and mTOR effector proteins (e.g., Akt at T308) at concentrations that matched those that inhibited cell growth. In MDA-MB-361 [breast: Her2(+) and PIK3CA mutant (E545K)], 30 nmol/L PKI-402 induced cleaved poly(ADP-ribose) polymerase (PARP), a marker for apoptosis. In vivo, PKI-402 inhibited tumor growth in MDA-MB-361, glioma (U87MG), and lung (A549) xenograft models. In MDA-MB-361, PKI-402 at 100 mg/kg (daily for 5 days, one round) reduced initial tumor volume of 260 mm(3) to 129 mm(3) and prevented tumor regrowth for 70 days. In MDA-MB-361 tumors, PKI-402 (100 mg/kg, single dose) suppressed Akt phosphorylation (at T308) and induced cleaved PARP. Suppression of phosphorylated Akt (p-Akt) was complete at 8 hours and still evident at 24 hours. Cleaved PARP was evident at 8 and 24 hours. In normal tissue (heart and lung), PKI-402 (100 mg/kg) had minimal effect on p-Akt, with no detectable cleaved PARP. Preferential accumulation of PKI-402 in tumor tissue was observed. Complete, sustained suppression of Akt phosphorylation may cause tumor regression in MDA-MB-361 and other xenograft models. We are testing whether dual PI3K/mTOR inhibitors can durably suppress p-Akt, induce cleaved PARP, and cause tumor regression in a diverse set of human tumor xenograft models. Mol Cancer Ther; 9(4); 976-84. (c)2010 AACR.
Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402.[Pubmed:19968288]
J Med Chem. 2010 Jan 28;53(2):798-810.
Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kalpha and mTOR, and excellent inhibition of cell proliferation in several human cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce apoptosis in cancer cells. In addition, 3 showed excellent in vivo efficacy in various human cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential anticancer therapy.